Registry for pulmonary alveolar proteinosis (PAP) patients
Part of Lungs & breathing clinical trials.
This study keeps a national record of people with pulmonary alveolar proteinosis (PAP). It includes one “snapshot” group and one group that follows people with autoimmune PAP and asks about symptoms and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (and your guardian, if needed) can sign consent; children may also give assent
- You have been diagnosed with PAP (by blood test, imaging, biopsy, or lung fluid testing)
- For the autoimmune-focused part, you have autoimmune PAP confirmed by a positive abnormal blood GM antibody test
- You have chest imaging (CT or X-ray) or test results that match PAP
- You do not have another serious health problem that would prevent finishing the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to deliver a protein called GM-CSF directly into the lungs through a tube during a bronchoscopy. It may help people with autoimmune pulmonary alveolar proteinosis (aPAP) breathe better and improve lung function.
This early-phase study tests a treatment that uses gene-corrected immune cells to treat hPAP, a rare lung condition. The goal is to check safety and see whether the treatment improves breathing and lung function.
This program provides an experimental inhaled medication to people with a rare lung condition called autoimmune pulmonary alveolar proteinosis (aPAP), where the immune system attacks the lungs. The treatment, molgramostim, is given through a nebulizer and may help improve breathing and reduce symptoms.
This study tests an inhaled medicine called molgramostim for children with autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung condition. The goal is to see if the drug can improve lung function and reduce the need for whole lung lavage (a washing procedure).
This study is a registry that collects information from people in China who have progressive pulmonary fibrosis (PPF), a lung condition that gets worse over time. It aims to better understand the disease and help doctors improve care.
This is a long-term study that enrolls people who have been diagnosed with pulmonary hypertension (high blood pressure in the lung arteries). It collects medical information over time to better understand the condition and what to expect.
Hear when a new Pulmonary Alveolar Proteinosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.